drugset / Trial / NCT07417566
A Study of DC6001 Tablet in Healthy Chinese Adult Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This study adopts a randomized, double-blind, parallel placebo-controlled dose-escalation design, consisting of two parts: Part 1 includes a single ascending dose (SAD) study plus a food effect (FE) study, and Part 2 is a multiple ascending dose (MAD) study.
Timeline
- Start
- 2026-01-01
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC6001 | Unknown | 2 mg | Oral |
| Subject | DC6001 | Unknown | 5 mg | Oral |
| Subject | DC6001 | Unknown | 10 mg | Oral |
| Subject | DC6001 | Unknown | 20 mg | Oral |
| Subject | DC6001 | Unknown | 40 mg | Oral |